Every 8-K that Incannex Healthcare Limited (IXHL) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow IXHL and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full IXHL filings page.
Incannex Healthcare Inc. (IXHL) reported a broad corporate update covering clinical progress, intellectual property and capital resources. The company has begun dosing patients in DReAMzz, a Phase 2 crossover dose‑optimization study of IHL‑42X for obstructive sleep apnea at 13 U.S. sites under Institutional Review Board approval, with an FDA‑reviewed protocol intended to support a later Phase 3 registration program.
Incannex highlighted prior positive Phase 2 RePOSA data in 121 subjects, where both low‑ and high‑dose IHL‑42X showed statistically significant improvements versus placebo in apnea‑hypopnea index and oxygen desaturation index, and noted the program’s Fast Track designation granted in December 2025. The U.S. Patent and Trademark Office has granted a composition and methods patent for IHL‑42X expiring July 9, 2040.
The company also reported progress for PSX‑001, its synthetic psilocybin candidate for generalized anxiety disorder, backed by a 73‑subject positive Phase 2 study, an open U.S. Investigational New Drug application for a Phase 2b trial, and recent regulatory engagement in the UK. As of August 31, 2026, Incannex held approximately $70 million in cash and cash equivalents with no debt, supported by more than A$11.2 million in 2026 Australian R&D tax incentive refunds.
Incannex Healthcare Inc. (IXHL) reports a clinical milestone for its lead sleep apnea candidate IHL-42X. The company has dosed the first patient in DReAMzz, a Phase 2 crossover dose-optimization study evaluating an oral fixed-dose combination of dronabinol and acetazolamide for obstructive sleep apnea.
The new study follows the earlier Phase 2 RePOSA trial, where IHL-42X produced statistically significant reductions in apnea-hypopnea index (AHI) versus placebo, with individual AHI reductions of up to 83% and an exceptional safety profile. IHL-42X has FDA Fast Track designation, and Incannex has activated 14 clinical sites in the United States for DReAMzz, with drug manufactured and regulatory and operational preparations completed.
DReAMzz is intended to characterize dose-response, optimize the treatment regimen, and support the design of a planned Phase 3 program. Incannex highlights IHL-42X as a potential oral treatment option for the large population affected by obstructive sleep apnea and positions this Phase 2 work as a step toward late-stage development.
Incannex Healthcare Inc. reported receiving a final A$5,102,788.30 cash refund under the Australian Government’s Research and Development Tax Incentive Program, following approval of its overseas findings and amendment of its FY25 income tax return. Together with a previously received A$6,039,162.43 refund, the company has obtained more than A$11.2 million in non-dilutive capital during 2026.
The company states that this funding enhances its strong cash position and debt-free balance sheet, providing additional financial flexibility to advance its clinical pipeline, including IHL-42X, IHL-675A and PSX-001, while pursuing shareholder-focused capital allocation initiatives.
Incannex Healthcare Inc. has begun screening participants in its DReAMzz randomized, crossover Phase 2 dose confirmation study of IHL-42X for obstructive sleep apnea. The first group of trial sites has approvals to screen patients, with additional sites to start as further approvals are obtained.
IHL-42X previously received Fast Track designation from the U.S. FDA. An earlier Phase 2 study showed statistically significant reductions in Apnea-Hypopnea Index versus placebo, with reductions of up to 83%, and improvements in patient‑reported outcomes such as fatigue and sleep-related impairment while maintaining a favorable safety profile.
DReAMzz is designed to optimize dosing and further link objective sleep metrics with patient-reported outcomes, generating data intended to support Phase III development and strengthen both the regulatory and commercial positioning of IHL-42X in a condition affecting an estimated one billion people globally.
Incannex Healthcare Inc. reports that the U.S. Patent and Trademark Office has granted a key patent titled “Compositions and Methods of Treatment for Obstructive Sleep Apnea” covering its proprietary IHL-42X oral combination therapy and related treatment methods. The patent has a baseline expiry date of 9 July 2040, and the company is exploring the potential for patent term extension following possible U.S. FDA approval. IHL-42X already has FDA Fast Track designation and positive Phase II data, and is advancing toward the DReAMzz Phase 2 dose optimisation study, which is intended to refine dosing and inform a planned Phase III program. Incannex describes obstructive sleep apnoea as a substantially underserved condition affecting an estimated one billion people globally, and views the strengthened U.S. patent position and ongoing clinical progress as enhancing the long-term commercial and strategic value of IHL-42X.
Incannex Healthcare Inc. reported receiving A$6,039,162.43 under the Australian Government’s Research and Development Tax Incentive Program for FY25 and expects a further approximately A$5.1 million in 2026. Combined, management highlights more than A$11.1 million in non-dilutive funding arriving in 2026.
The company notes that this cash is being received without issuing additional shares or taking on debt, supporting its debt-free balance sheet and existing cash position. Management states that the proceeds will help advance key clinical programs, including the DReAMzz study for lead candidate IHL-42X in obstructive sleep apnea, as well as IHL-675A for inflammatory conditions and PSX-001 for generalized anxiety disorder, while also supporting an active share repurchase program.
Incannex Healthcare Inc. filed a current report highlighting that Alliance Global Partners has initiated independent equity research coverage on the company. The AGP report reviews Incannex’s clinical pipeline, strategy, market opportunities and growth prospects, including lead programs IHL-42X for obstructive sleep apnoea and PSX-001 for generalized anxiety disorder.
Incannex views this research coverage as an important step in expanding awareness of its clinical programs among institutional and retail investors. The company notes that analyst opinions are solely those of Alliance Global Partners, that AGP has received compensation for providing investment banking services, and includes customary forward-looking statement and risk factor cautions.
Incannex Healthcare Inc. has officially started its DReAMzz clinical study of IHL-42X for obstructive sleep apnea. This crossover dose-optimization trial aims to refine the dosing profile and inform the design of a planned Phase III program.
The company has identified all 14 clinical sites, completed manufacturing of IHL-42X drug product, secured necessary import and export permits, and onboarded a global distribution partner to support site activation and patient dosing. DReAMzz builds on the prior Phase II RePOSA trial, where IHL-42X showed statistically significant and clinically meaningful reductions in apnea-hypopnea index, with improvements in oxygenation, sleep quality, fatigue and other patient-reported outcomes.
IHL-42X has previously received U.S. FDA Fast Track designation for obstructive sleep apnea, reflecting the seriousness of the condition and unmet medical need. DReAMzz is intended to further optimize and de-risk the Phase III pathway and forms part of Incannex’s broader strategy to develop combination therapies for chronic conditions.
Incannex Healthcare Inc. filed a Form 8-K to share that it has won the “Best New Technology Solution for Drug Development” honor in the 10th annual MedTech Breakthrough Awards. The award recognizes its lead drug candidate IHL-42X, an oral fixed-dose combination therapy being developed for obstructive sleep apnea.
In the Phase 2 RePOSA trial, IHL-42X produced statistically significant and clinically meaningful reductions in apnea-hypopnea index, with better oxygenation, sleep quality, and fatigue outcomes. Incannex highlights this recognition as supporting its strategy of developing differentiated combination medicines, including IHL-42X for sleep apnea, IHL-675A for inflammatory conditions such as rheumatoid arthritis, and PSX-001 for generalized anxiety disorder.
Incannex Healthcare Inc. furnished a press release describing progress in its PSX-001 oral synthetic psilocybin program for Generalized Anxiety Disorder and its alignment with a new White House Executive Order on psychedelic treatments for serious mental illness.
The company reports PSX-001 showed statistically significant, clinically meaningful benefits across all primary and secondary endpoints in a completed Phase 2 trial involving 73 patients, and notes its U.S. IND is active. Incannex states it is well-funded with over $70 million in cash and no debt, and believes the Executive Order’s directives to prioritize review, enable Right to Try pathways, and initiate DEA rescheduling after successful Phase 3 may reduce regulatory and commercial risk for psilocybin-based therapies.
Incannex Healthcare Inc. has reactivated its previously approved share repurchase program and has already bought back shares over the past two trading days. The board decided to restart buybacks because it believes the company’s market value is too low relative to its cash, clinical progress, and future prospects.
Incannex reports approximately $75 million in cash on hand and no debt following recent financing, giving it flexibility to fund development of IHL-42X for obstructive sleep apnea and PSX-001 for generalized anxiety disorder while repurchasing stock. As of December 31, 2025, about $18.5 million remained available under the repurchase authorization.
The company plans to use the program opportunistically based on market conditions, trading volumes, available capital and broader needs. The buyback authorization does not require any minimum level of repurchases and may be modified, suspended or discontinued at the company’s discretion.
Incannex Healthcare Inc. filed a current report describing a new partnership with the AASM Foundation to support sleep apnea research as its lead drug IHL-42X advances. The company is joining the AASM Foundation’s Corporate Recognition Program and sponsoring a Focused Projects Grant for Junior Investigators on the diagnosis, management, and treatment of sleep apnea, to be awarded in 2026.
The filing highlights recent milestones for IHL-42X, an oral fixed-dose combination of dronabinol and acetazolamide being developed for obstructive sleep apnea, including positive Phase 2 results, FDA Fast Track designation, and progression into the DReAMzz Phase 2 crossover dose-optimisation study ahead of a planned Phase 3 program. Incannex also outlines a broader pipeline that includes IHL-675A for rheumatoid arthritis and PSX-001, a synthetic psilocybin therapy for generalized anxiety disorder.
Incannex Healthcare is highlighting a strong balance sheet following a recently completed financing. The company now holds approximately $75 million in cash with no debt, which management contrasts with a market capitalization of about $46 million, implying a negative enterprise value.
Proceeds from the financing are expected to fund the DReAMzz Phase 2 crossover dose-optimization study for lead candidate IHL-42X in obstructive sleep apnea, while preserving most existing cash for an optimized Phase 3 program. Incannex is also advancing PSX-001 for generalized anxiety disorder under an open FDA IND, and maintains a board-approved share buyback program with remaining capacity. Management views institutional participation in the financing and the company’s cash-rich, debt-free position as external validation of its clinical pipeline and strategy.
Incannex Healthcare Inc. has regained compliance with Nasdaq’s minimum bid price requirement, securing its continued listing on the Nasdaq Capital Market. Nasdaq confirmed the company met the rule after its stock closed at or above $1.00 per share for eleven consecutive business days from February 27 through March 13, 2026.
The company highlights having approximately $75 million in cash and no debt, supporting advancement of its clinical pipeline. Key programs include IHL-42X for obstructive sleep apnea, IHL-675A for inflammatory conditions such as rheumatoid arthritis, and PSX-001 for generalized anxiety disorder.
Incannex Healthcare Inc. entered into a securities purchase agreement for a registered direct offering to institutional investors. The company will sell 1,997,285 shares of common stock, pre-funded warrants for up to 2,715 additional shares, and common stock warrants to purchase up to 2,000,000 shares.
The securities are priced at a combined purchase price of $5.0 per share and accompanying warrant, or $4.9999 per pre-funded warrant and accompanying warrant, for expected gross proceeds of about $10 million before fees and expenses. The common warrants have a $6.50 exercise price and a five-year term. Warrant exercises are subject to 4.99% or, at the investor’s option, 9.99% ownership caps, and the company agreed to a 60-day restriction on issuing additional equity after closing.
Incannex Healthcare Inc. has ended its at-the-market common stock sales arrangement with Curvature Securities and A.G.P./Alliance Global Partners, which allowed it to sell shares from time to time through these agents. Over the life of this Sales Agreement, Incannex raised approximately $108.4 million in aggregate gross proceeds, and the arrangement was terminable at will by the company with no penalty.
The company also updated its corporate investor presentation, now available via its investor relations website and furnished as an exhibit, and issued a press release describing an enhanced Phase 2 dose-optimisation study, which is provided as another exhibit.
Incannex Healthcare Inc. approved and implemented a 1-for-30 reverse stock split of its common stock. Every 30 shares will be combined into 1 share at 4:01 p.m. Eastern Time on February 26, 2026, with trading on a split-adjusted basis beginning February 27, 2026.
The reverse split will reduce outstanding common shares from approximately 358,329,368 as of February 20, 2026 to about 11,944,313, without changing the total number of authorized shares or the par value. Fractional positions will be rounded up to the next whole share, with no cash paid for fractions.
The company states that the reverse split is intended to increase the per-share trading price of its stock to help regain compliance with Nasdaq’s minimum bid price requirement, while existing shareholders retain the same proportional ownership after the adjustment.
Incannex Healthcare Inc. filed a current report to note that, on January 29, 2026, it announced additional appointments to its Clinical Advisory Board. The company states that more details are provided in a press release, which is attached as Exhibit 99.1 and incorporated by reference into the filing.
Incannex Healthcare Inc. filed a current report to note a corporate development related to its PSX-001 program. On January 22, 2026, the company announced it has formed a Clinical Advisory Board to support this program, indicating a step toward organizing expert guidance around its clinical strategy. Details about the advisory board’s members, role, and expected contributions are provided in a press release dated January 22, 2026, which is attached to the report as Exhibit 99.1.
Incannex Healthcare Inc. reported the results of its 2025 Annual Meeting of Stockholders held virtually on January 15, 2026. Out of 347,705,507 shares of common stock issued and outstanding as of the October 24, 2025 record date, 119,550,295 shares, or approximately 34.38% of eligible shares, were present in person or by proxy, establishing a quorum for business.
Stockholders elected Dr. George Anastassov and Robert Clark as directors to serve until the 2028 Annual Meeting and until their successors are duly elected and qualified. Dr. Anastassov received 55,032,850 votes for and 3,295,276 votes withheld, while Robert Clark received 56,220,279 votes for and 2,107,847 votes withheld; each director election had 61,222,169 broker non-votes. Stockholders also ratified the appointment of Grant Thornton Audit Pty Ltd as the independent registered public accounting firm for the fiscal year ending June 30, 2026, with 110,346,963 votes for, 7,877,386 votes against, and 1,325,946 votes abstaining.
Incannex Healthcare Inc. reported that on January 15, 2026 it won a Research and Development Award for its obstructive sleep apnea program in the 2025 Clinical Trials Arena Excellence Awards. This recognition highlights the company’s work in developing treatments for obstructive sleep apnea.
The company also noted that additional details about the award and the program are provided in a press release, which is included as Exhibit 99.1 to this report and incorporated by reference.
Incannex Healthcare Inc. filed a current report to disclose that, on January 14, 2026, it issued a press release titled “Incannex Healthcare Inc. Delivers Transformational 2025 Progress and Outlines Well-Funded Outlook for 2026.” The press release is attached as an exhibit and incorporated by reference, and is described as outlining the company’s 2025 progress and its well-funded outlook for 2026.
Incannex Healthcare Inc. reported that its 2025 annual meeting of stockholders did not have enough common shares present or represented by proxy to reach a quorum. The shortfall was primarily tied to Proposal No. 2, the auditor ratification proposal, which was treated as a non-routine item because of an administrative error by the company’s transfer agent.
As a result, the annual meeting was adjourned and is scheduled to reconvene virtually on January 15, 2026 at 11:00 a.m. Gulf Standard Time via live audio webcast at www.meetnow.global/MD59M9U. Incannex is working with the transfer agent and other parties to have the auditor ratification proposal reclassified as routine, which would allow brokers and other nominees to use discretionary voting authority for shares held in street name.
During the adjournment, the company will continue soliciting proxies for all proposals described in its proxy statement. Proxies already submitted will remain valid and will be voted at the reconvened meeting unless properly revoked, so stockholders who have already voted do not need to take further action.
Incannex Healthcare Inc. filed a current report to let investors know it has issued a new shareholder update. On October 30, 2025, the company provided an overview for shareholders that highlights its clinical progress, capital discipline, and end‑of‑year 2025 strategic focus.
The details of this update are contained in a press release attached as Exhibit 99.1 to the report, which is incorporated by reference into the filing. The company’s common stock continues to trade on the Nasdaq Stock Market under the symbol IXHL.
Incannex Healthcare (IXHL) disclosed that Nasdaq granted a 180-day extension to regain compliance with the minimum bid price requirement.
The company reported this under Item 8.01 on October 22, 2025. Further details are available in a press release furnished as Exhibit 99.1.
Incannex Healthcare (IXHL) reported a Nasdaq compliance update. The company received a second 180-day grace period, until April 20, 2026, to regain compliance with Nasdaq’s $1.00 minimum bid price rule. The extension follows IXHL’s July transfer from the Nasdaq Global Market to the Nasdaq Capital Market, where it meets all initial listing standards except the bid price requirement.
IXHL can regain compliance if its closing bid price is at least $1.00 for 10 consecutive business days, which Nasdaq may extend to 20 days at its discretion. The company stated it intends to cure the deficiency, including by effecting a reverse stock split if necessary. IXHL’s shares continue to trade on the Nasdaq Capital Market while it remains subject to the market’s other continued listing requirements.
Incannex Healthcare Inc. reported positive results from a Phase 2 clinical trial of its investigational therapy PSX-001 (Psi-GAD) for generalized anxiety disorder. The company disclosed the outcome as an other event and directed readers to a detailed press release for more information, indicating that the trial met encouraging benchmarks for this mental health condition. This update highlights progress in Incannex’s clinical development pipeline, although specific efficacy or safety data are contained in the accompanying press release rather than in this report.
Incannex Healthcare Inc. reported that its board has authorized a $20 million share repurchase program. This means the company now has approval to buy back up to that amount of its own common stock, which can reduce the number of shares held by the public over time if the program is used. The update was shared as an other event, with additional details provided in a related press release referenced in the filing.
Incannex Healthcare Inc. (Nasdaq: IXHL) filed a Form 8-K on 8 Aug 2025 announcing that it has received “positive patient-reported outcomes and compelling Phase 2 efficacy data” for IHL-42X, its drug candidate for obstructive sleep apnoea (OSA). The disclosure is provided via a press release attached as Exhibit 99.1 and incorporated under Item 8.01; no financial statements or other quantitative information accompany the notice. The report, signed by CEO Joel Latham, signals meaningful clinical progress for a core pipeline asset but leaves key metrics—statistical significance, safety profile and regulatory timeline—undisclosed. Investors must consult the referenced press release for comprehensive data and next-step development plans.
Incannex Healthcare (NASDAQ: IXHL), an emerging growth company, announced the appointment of Dr. Douglas B. Kirsch to its Clinical Advisory Board on June 24, 2025, specifically to support its Obstructive Sleep Apnea program.
Key details from the 8-K filing:
- The company is listed on The Nasdaq Stock Market with common stock at $0.0001 par value per share
- Headquartered in Norwest, NSW, Australia
- Joel Latham serves as Chief Executive Officer and President
- The company has elected emerging growth company status
- The appointment represents a strategic expansion of expertise in sleep medicine, potentially strengthening the company's clinical development programs
This strategic addition to the advisory board signals Incannex's continued focus on advancing its sleep apnea therapeutic programs and enhancing its clinical development capabilities.